King Pharmaceuticals Research and Development, Inc. v. SICOR Inc.
1:05-cv-00337
Overview
Parties
Defendant
Teva Pharmaceuticals Industries, LTD. Operating Company
Represented By
0 Attorneys ListedTeva Pharmaceuticals USA, Inc. Operating Company
Represented By
0 Attorneys ListedSICOR Pharmaceuticals, Inc. Operating Company
Represented By
2 Attorneys ListedDoungamon Fon Muttamara-Walker
District of Columbia Office of
Administrative Hearings, 441 Fourth Street, N.W.
Shaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
SICOR Inc. Operating Company
Represented By
2 Attorneys ListedDoungamon Fon Muttamara-Walker
District of Columbia Office of
Administrative Hearings, 441 Fourth Street, N.W.
Shaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Plaintiff
Astellas Pharma US, Inc. Operating Company
Represented By
1 Attorneys ListedADDRESS EXPIRED / UNKNOWN
ADDRESS EXPIRED / UNKNOWN, (302) 888-6800
Astellas US LLC Operating Company
Represented By
1 Attorneys ListedADDRESS EXPIRED / UNKNOWN
ADDRESS EXPIRED / UNKNOWN, (302) 888-6800
King Pharmaceuticals Research and Development Inc. Operating Company
Represented By
7 Attorneys ListedRogowski Law LLC
501 Silverside Road, Suite 11, Wilmington, DE 19809
Novak Druce Connolly Bove + Quigg LLP
The Nemours Building, 1007 North Orange Street
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 9 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 5,070,877 A Asserted | US Continuation / Sibling | View Official Patent → |
| 🇨🇦 Canada | CA 000596950 A | Canada Counterpart | View Official Patent → |
| 🇨🇦 Canada | CA 1305922 C | Canada Counterpart | View Official Patent → |
| 🇪🇺 European Patent Office (UPC States) | EP 1,989,030,396 | European Counterpart (EP) | View Official Patent → |
| 🇪🇺 European Patent Office (UPC States) | EP 354,638 A3 | European Counterpart (EP) | View Official Patent → |
| 🇯🇵 Japan | JP 2015143 A | Japan Counterpart | View Official Patent → |
| 🇯🇵 Japan | JP 2914454 B2 | Japan Counterpart | View Official Patent → |
| 🇯🇵 Japan | JP 9257923 A | Japan Counterpart | View Official Patent → |
| 🇺🇸 United States | US 23,121,788 A | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5070877
Novel method of myocardial imaging
|
Filed: 1989-03-29
Issued: 1991-12-10
|
Expired (Term Ended)
+50d PTA
Expires: 2009-05-18
|
|
|
US5731296
Selective vasodilation by continuous adenosine infusion
|
Filed: 1993-03-15
Issued: 1998-03-24
|
Expired (Term Ended)
Expires: 2013-03-15
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
17
Dispositive
7
Granted
0
Denied
2
Pending / Review
11
Motions by Category
Key Dispositive Motions & Rulings